Issue |
Med Sci (Paris)
Volume 26, Number 5, Mai 2010
|
|
---|---|---|
Page(s) | 516 - 521 | |
Section | M/S revues | |
DOI | https://doi.org/10.1051/medsci/2010265516 | |
Published online | 15 May 2010 |
GSK-3β : une kinase au cœur des maladies neuro-dégénératives ?
GSK-3β: a central kinase for neurodegenerative diseases ?
Institut de pharmacologie moléculaire et cellulaire, 660, route des Lucioles, Sophia Antipolis, 06560 Valbonne, France
Le vieillissement de la population entraîne une augmentation spectaculaire de l’incidence des maladies neurodégénératives dans les pays industrialisés. L’implication de la GSK-3β (glycogen synthase kinase) dans la pathogenèse de la maladie d’Alzheimer est bien établie, mais il semble également évident que la dérégulation de l’activité de la GSK-3β pourrait être étroitement liée à d’autres maladies neurodégénératives, comme les maladies de Parkinson et de Huntington. Dans cette revue, je résumerai les découvertes permettant de définir l’activité de la GSK-3β comme étant le point de convergence des processus à l’origine de ces maladies. L’inhibition de l’activité de la GSK-3β en tant qu’approche thérapeutique possible sera également discutée.
Abstract
Neurodegenerative diseases are more and more prevalent in our aging societies. There is strong evidence that glycogen synthase kinase (GSK)-3β plays a crucial role in Alzheimer’s disease (AD). Indeed, it is involved in the regulation of the two major neuropathological hallmarks present in the brains of AD patients. Interestingly, the kinase has been implicated in multiple cellular processes and linked with the pathogenesis and neuronal loss in several neurodegenerative diseases, including Parkinson’s and Huntington’s diseases, in which abnormally elevated levels of GSK-3β activity have been reported. In this review, we will provide an overview of the current data pointing out the convergent role of GSK-3β in the neuropathological pathways of these diseases. We will also discuss the rationale for the development of specific inhibitors with therapeutic potentials for such devastating human diseases.
© 2010 médecine/sciences - Inserm / SRMS
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.